Enveric Biosciences (NASDAQ:ENVB) stock surged 13.4% in premarket trading Thursday after the company announced new mechanistic data for its lead drug candidate EB-003, demonstrating the compound’s activation of dual signaling pathways linked to antidepressant and anxiolytic effects.
